BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SBFM upcoming catalysts

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 1 FDA event(s). Subscribe to SBFM (.ics).

Drugs: HEC585 A, HEC585 B

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Sunshine Lake Pharma Co., Ltd. SBFMNCT05139719 A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung DisProgressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)recruiting110
2027-01-14 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT07261644 A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)Ankylosing Spondylitisrecruiting500
2027-02 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06323213 Efficacy and Safety Study of 610 in Patients With Severe AsthmaAsthmarecruiting480
2027-02 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06680947 A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaAsthmaactive not recruiting225

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-29FDA approvalapprovedSUNSHINE LAKE PHARMA CO LTD SBFMLANGLARAApproved 2026-04-29: LANGLARA (BLA761412 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06-30 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT07042126 Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic DermatitisDermatitis, Atopicrecruiting180
2026-05-25P1/P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06324812 Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic DermatitisDermatitis, Atopiccompleted128
2025-12 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06639295 A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsSinusitis; Nasal Polypsactive not recruiting243

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.